Madrigal Pharmaceuticals

liver

Biotech

Madrigal pays Pfizer $50M for MASH drug with combo potential

Madrigal paid $50 million for a DGAT2i inhibitor that the biopharma intends to combine with its approved liver disease drug Rezdiffra.

James Waldron Jan 9, 2026 10:50am

ChatGPT said Low-poly magenta liver model centered on a pale blue background patterned with sketchy dollar signs suggestin

Fierce Pharma

Big Pharma bets big on MASH with a new combo playbook

Oct 17, 2025 9:30am

liver

Madrigal pens $2B deal for CSPC's GLP-1, eyes Rezdiffra pairing

Jul 30, 2025 7:35am

Charming view of the seaside resort town of Kas in Turkey Romantic lighthouse at the entrance to the port and a paraglider f

AIRNA appoints Elevidys architect as CMO—Chutes & Ladders

Apr 18, 2025 8:30am

Paragliding near Tu Le valley with landscape with green and yellow rice fields and blue cloudy sky North- Vietnam

Prothena promotes one exec while another leaves—Chutes & Ladders

Oct 4, 2024 8:00am

proclaim red announcement

Aligos MASH prospect slashes liver fat in phase 2

Sep 19, 2024 1:00pm